Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation The PEPTIC Randomized Clinical Trial

被引:142
|
作者
Young, Paul J. [1 ,2 ,21 ,22 ]
Bagshaw, Sean M. [3 ,23 ]
Forbes, Andrew B. [4 ]
Nichol, Alistair D. [5 ,6 ,7 ,24 ,25 ,26 ]
Wright, Stephen E. [8 ,27 ]
Bailey, Michael [6 ,9 ]
Bellomo, Rinaldo [6 ,9 ,10 ,28 ,29 ,30 ,33 ]
Beasley, Richard [1 ,31 ]
Brickell, Kathy [7 ,32 ]
Eastwood, Glenn M. [10 ,33 ]
Gattas, David J. [11 ,12 ,34 ]
Van Haren, Frank [13 ,35 ]
Litton, Edward [14 ,36 ]
Mackle, Diane M. [1 ,37 ]
McArthur, Colin J. [1 ,15 ,37 ,38 ]
McGuinness, Shay P. [1 ,16 ,37 ,38 ]
Mouncey, Paul R. [17 ,39 ]
Navarra, Leanlove [1 ,37 ]
Opgenorth, Dawn [3 ,40 ]
Pilcher, David [5 ,6 ,18 ,41 ,42 ]
Saxena, Manoj K. [12 ,19 ,43 ,44 ]
Webb, Steve A. [20 ,45 ]
Wiley, Daisy [17 ,46 ]
Rowan, Kathryn M. [17 ,47 ]
机构
[1] Med Res Inst New Zealand, Wellington, New Zealand
[2] Wellington Hosp, Intens Care Unit, Private Bag 7902, Wellington, New Zealand
[3] Univ Alberta Hosp, Dept Crit Care Med, Edmonton, AB, Canada
[4] Monash Univ, Biostat Unit, Melbourne, Vic, Australia
[5] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia
[6] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia
[7] Univ Coll Dublin, St Vincents Hosp, Clin Res Ctr, Dublin, Ireland
[8] Freeman Rd Hosp, Intens Care Unit, Newcastle Upon Tyne, Tyne & Wear, England
[9] Univ Melbourne, Melbourne, Vic, Australia
[10] Austin Hosp, Intens Care Unit, Heidelberg, Vic, Australia
[11] Royal Prince Alfred Hosp, Intens Care Unit, Camperdown, NSW, Australia
[12] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia
[13] Canberra Hosp, Intens Care Unit, Canberra, ACT, Australia
[14] Fiona Stanley Hosp, Intens Care Unit, Murdoch, WA, Australia
[15] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand
[16] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand
[17] Intens Care Natl Audit & Res Ctr, London, England
[18] Australian & New Zealand Intens Care Soc, Ctr Outcome & Resource Evaluat, Camberwell, Australia
[19] Bankstown Hosp, Intens Care Unit, Bankstown, Australia
[20] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia
[21] Med Res Inst New Zealand, Wellington, New Zealand
[22] Wellington Hosp, Wellington, New Zealand
[23] Univ Alberta Hosp, Edmonton, AB, Canada
[24] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia
[25] Alfred Hosp, Melbourne, Vic, Australia
[26] St Vincents Hosp, Dublin, Ireland
[27] Dorset Cty Hosp, Dorchester, England
[28] Austin Hosp, Heidelberg, Vic, Australia
[29] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia
[30] Univ Melbourne, Melbourne, Vic, Australia
[31] Med Res Inst New Zealand, Wellington, New Zealand
[32] St Vincents Hosp, Dublin, Ireland
[33] Austin Hosp, Heidelberg, Vic, Australia
[34] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[35] Canberra Hosp, Canberra, ACT, Australia
[36] Fiona Stanley Hosp, Perth, WA, Australia
[37] Med Res Inst New Zealand, Wellington, New Zealand
[38] Auckland City Hosp, Auckland, New Zealand
[39] Intens Care Audit & Res Ctr, London, England
[40] Univ Alberta Hosp, Edmonton, AB, Canada
[41] Monash Univ, Alfred Hosp, Australian & New Zealand Intens Care Soc Ctr Outc, Melbourne, Vic, Australia
[42] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia
[43] Univ New South Wales, Bankstown Hosp, Intens Care Unit, Sydney, NSW, Australia
[44] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia
[45] Royal Perth Hosp, Perth, WA, Australia
[46] Intens Care Audit & Res Ctr, London, England
[47] Intens Care Audit & Res Ctr, London, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2020年 / 323卷 / 07期
基金
加拿大健康研究院;
关键词
INTENSIVE-CARE; PANTOPRAZOLE; ANTAGONISTS;
D O I
10.1001/jama.2019.22190
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H(2)RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown. Objective To compare in-hospital mortality rates using PPIs vs H(2)RBs for stress ulcer prophylaxis. Design, Setting, and Participants Cluster crossover randomized clinical trial conducted at 50 ICUs in 5 countries between August 2016 and January 2019. Patients requiring invasive mechanical ventilation within 24 hours of ICU admission were followed up for 90 days at the hospital. Interventions Two stress ulcer prophylaxis strategies were compared (preferential use with PPIs vs preferential use with H(2)RBs). Each ICU used each strategy sequentially for 6 months in random order; 25 ICUs were randomized to the sequence with use of PPIs and then use of H(2)RBs and 25 ICUs were randomized to the sequence with use of H(2)RBs and then use of PPIs (13436 patients randomized by site to PPIs and 13392 randomized by site to H(2)RBs). Main Outcomes and Measures The primary outcome was all-cause mortality within 90 days during index hospitalization. Secondary outcomes were clinically important upper gastrointestinal bleeding, Clostridioides difficile infection, and ICU and hospital lengths of stay. Results Among 26 982 patients who were randomized, 154 opted out, and 26 828 were analyzed (mean [SD] age, 58 [17.0] years; 9691 [36.1%] were women). There were 26 771 patients (99.2%) included in the mortality analysis; 2459 of 13415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13 356 patients (17.5%) in the H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI, 1.00 to 1.10]; absolute risk difference, 0.93 percentage points [95% CI, -0.01 to 1.88] percentage points; P = .054). An estimated 4.1% of patients randomized by ICU site to PPIs actually received H(2)RBs and an estimated 20.1% of patients randomized by ICU site to H(2)RBs actually received PPIs. Clinically important upper gastrointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [95% CI, 0.57 to 0.92]; absolute risk difference, -0.51 percentage points [95% CI, -0.90 to -0.12 percentage points]; P = .009). Rates of Clostridioides difficile infection and ICU and hospital lengths of stay were not significantly different by treatment group. One adverse event (an allergic reaction) was reported in 1 patient in the PPI group. Conclusions and Relevance Among ICU patients requiring mechanical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectively, a difference that did not reach the significance threshold. However, study interpretation may be limited by crossover in the use of the assigned medication.
引用
收藏
页码:616 / 626
页数:11
相关论文
共 43 条
  • [1] Proton Pump Inhibitors vs Histamine-2 Receptor Blockers for Stress Ulcer Prophylaxis in Critically Ill Patients Issues of Interpretability in Pragmatic Trials
    Rice, Todd W.
    Kripalani, Sunil
    Lindsell, Christopher J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (07): : 611 - 613
  • [2] Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study
    Huang, Minqiang
    Han, Ming
    Han, Wei
    Kuang, Lei
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (06)
  • [3] Proton Pump Inhibitors Versus Histamine-2 Receptor Blockers for Stress Ulcer Prophylaxis on In-hospital Mortality Among Intensive Care Unit Patients Hospitalized for Major Adverse Cardiovascular and Cerebrovascular Events: Retrospective Cohort Study
    Pu, Lanxiang
    Jia, Ting
    Su, Shili
    Yang, Liang
    Yao, Hong
    Su, Yujie
    Chen, Zhaowen
    CLINICAL THERAPEUTICS, 2024, 46 (09) : 677 - 682
  • [4] The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: A meta-analysis
    Lin, Pei-Chin
    Chang, Chia-Hsuin
    Hsu, Ping-I
    Tseng, Pi-Lai
    Huang, Yaw-Bin
    CRITICAL CARE MEDICINE, 2010, 38 (04) : 1197 - 1205
  • [5] PROTON PUMP INHIBITORS VS HISTAMINE TYPE 2 RECEPTOR BLOCKERS FOR STRESS ULCER PROPHYLAXIS IN MECHANICALLY VENTILATED PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
    Banna, Soumya
    Schenck, Christopher
    Namburar, Sathvik
    Shahu, Andi
    Thomas, Alexander W.
    Heck, Cory
    Ali, Tariq
    Miller, Paul Elliott
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1276 - 1276
  • [6] Incidence of Thrombocytopenia Between Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in Critically Ill, Mechanically Ventilated Patients Receiving Stress-Ulcer Prophylaxis
    Robles, Julian
    Wall, Geoffrey
    Laageide, Leah
    Akhtar, Zaheer
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S314 - S314
  • [7] A cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors versus histamine-2 receptor blockers for ulcer prophylaxis therapy in the intensive care unit (PEPTIC study): study protocol
    Young, Paul J.
    Bagshaw, Sean M.
    Forbes, Andrew
    Nichol, Alistair
    Wright, Stephen E.
    Bellomo, Rinaldo
    Bailey, Michael J.
    Beasley, Richard W.
    Eastwood, Glenn M.
    Festa, Marino
    Gattas, David
    van Haren, Frank
    Litton, Edward
    Mouncey, Paul R.
    Navarra, Leanlove
    Pilcher, David
    Mackie, Diane M.
    McArthur, Colin J.
    McGuinness, Shay P.
    Saxena, Manoj K.
    Webb, Steve
    Rowan, Kathryn M.
    CRITICAL CARE AND RESUSCITATION, 2018, 20 (03) : 182 - 189
  • [8] Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial
    van Diepen, Sean
    Coulson, Tim
    Wang, Xiaoming
    Opgenorth, Dawn
    Zuege, Danny J.
    Harris, Jo
    Agyemang, Malik
    Niven, Daniel J.
    Bellomo, Rinaldo
    Wright, Stephen E.
    Young, Paul J.
    Bagshaw, Sean M.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 62 (02)
  • [9] Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review
    Begg, Maha
    Tarhuni, Mawada
    Fotso, Monique N.
    Gonzalez, Natalie A.
    Sanivarapu, Raghavendra R.
    Osman, Usama
    Kumar, Abishek Latha
    Sadagopan, Aishwarya
    Mahmoud, Anas
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [10] Hospitalized patients on proton pump inhibitors for stress ulcer prophylaxis have a higher risk of Clostridioides difficile infection compared with those on histamine-2 receptor antagonists
    Wu, L. -H.
    Wang, J. -L.
    Liu, Y. -H.
    Su, C. -C.
    Yang, Y-H. K.
    Lin, S. -J.
    Cheng, C. -L.
    JOURNAL OF HOSPITAL INFECTION, 2024, 154 : 9 - 17